Rimon Therapeutics Ltd.
This article was originally published in Start Up
Executive Summary
Rimon Therapeutics set out to discover polymers that would achieve a therapeutic effect without acting like drugs; that is, they would act locally, wouldn't be metabolized, and wouldn't be soluble. The company has initially focused its product development efforts on wound healing, with two technologies, polymer beads that induce angiogenesis, and a polymer that sequesters matrix metalloproteinases.
You may also be interested in...
Biocoatings: Not Just the Icing on the Cake
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Cosmetic And Personal Care Trademark Review: 7 February
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Year Ahead Could Prove Rough For Private Biotech Financing
The second half of 2022 saw a downturn in fundraising by venture capital firms, and panelists at BIO CEO said that could spell trouble in 2023.